Flotetuzumab
mAbexperimentalMulti-specific
Flotetuzumab is a bispecific antibody designed for the treatment of acute myeloid leukemia. — Wikipedia
Clinical trial activity
8 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
3
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2014 (NCT02152956)
Timeline
Indications
Studied for
- Hodgkin Disease · Phase 2
- Leukemia · Phase 1
- Leukemia, Biphenotypic, Acute · Phase 2
- Leukemia, Hairy Cell · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 2
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 2
- Leukemia, Myeloid, Acute · Phase 2
- Mastocytosis, Systemic · Phase 2
- Neoplasms · Phase 2
- Plasmacytoma · Phase 2
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
- Receptors, Interleukin-3 · Phase 2
Mechanism of action
CD3E activator
- T cell surface glycoprotein CD3BINDING AGENT
T cell surface glycoprotein CD3 binding agent
- Interleukin-3 receptor subunit alphaBINDING AGENT
Interleukin-3 receptor subunit alpha binding agent
- Interleukin-3 receptor subunit alphaINHIBITOR
IL3RA inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaFlotetuzumab ↗
- ChEMBLCHEMBL3990038 ↗
Also known as
- mgd006
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05506956 | Phase 1 | Oct 20, 2022 | Johns Hopkins University, MacroGenics, National Cancer Institute (NCI) |
| NCT05063123 | Phase 2 | Jan 31, 2022 | Erasmus University Rotterdam, HOVON - Dutch Haemato-Oncology Association |
| NCT04582864 | Phase 2 | May 20, 2021 | MacroGenics, National Cancer Institute (NCI), Washington University in St. Louis |
| NCT04681105 | Phase 1 | Dec 30, 2020 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT04158739 | Phase 1 | Nov 9, 2019 | National Cancer Institute (NCI) |
| NCT03739606 | Phase 2 | Jun 10, 2019 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02152956 | Phase 1 | May 1, 2014 | Institut Paoli-Calmettes, MacroGenics, Servier, Washington University in St. Louis |
| NCT04678466 | N/A | — | MacroGenics |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 5 | 1 | 2 | 2019 |
| MacroGenics | For profit | 4 | 2 | 3 | 2014 |
| City of Hope National Medical Center | Academic/Hospital | 2 | 2 | 2 | 2019 |
| Washington University in St. Louis | Academic/Hospital | 2 | 1 | 2 | 2014 |
| Erasmus University Rotterdam | Academic/Hospital | 1 | 0 | 1 | 2022 |
| HOVON - Dutch Haemato-Oncology Association | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Institut Paoli-Calmettes | Academic/Hospital | 1 | 0 | 1 | 2014 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Servier | For profit | 1 | 0 | 1 | 2014 |
9 organizations
Page 1 / 1